Loading
A phase 2 trial of sacituzumab govitecan and pegfilgrastim in triple-negative breast cancer, run by Yeon Hee Park, now recruiting.
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06616987 by Yeon Hee Park, with a registry enrolment figure of 40 participants, started 2025-07-03 and due to reach its primary completion in 2027-06-30. Interventions recorded: Sacituzumab Govitecan with pegfilgrastim. Conditions listed: Breast Cancer Metastatic. Triple-negative eligibility wording from the registry: "Histologically confirmed TNBC per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria based on local testing on the most recent analyzed biopsy". Sites: South Korea. No results are recorded here; the registry entry is the source.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.